Key Takeaways
- • Calyxo closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors, advancing its kidney stone treatment platform for urologists.
- • The round includes continued backing from existing investors Questa Capital, Avidity Partners, and CRG, signaling sustained confidence in the company's clinical and commercial trajectory.
- • Calyxo positions itself as an innovation-driven medical device company focused on delivering superior clinical outcomes in urological care, a specialized but established market segment.
- • The Series F funding reflects ongoing capital availability in the medical device sector, particularly for companies addressing specific procedural improvements in established surgical markets.
Summary
Calyxo, a Pleasanton, California-based medical device company, announced the closing of a $40 million Series F financing round on April 15, 2026. The round was led by Ally Bridge Group and Janus Henderson Investors, with continued participation from existing backers Questa Capital, Avidity Partners, and CRG.
The company specializes in kidney stone treatment solutions designed to enhance clinical outcomes for urologists. According to its positioning, Calyxo focuses on delivering what it characterizes as "paradigm-shifting solutions" that enable practitioners to achieve outcomes safely, effectively, and efficiently. The company's focus on a specific procedural market within urology—kidney stone intervention—represents a targeted approach to medical device innovation rather than a broad-based platform play.
This Series F round demonstrates sustained investor appetite for specialized medical device companies addressing defined clinical needs. The participation of both new lead investors (Ally Bridge Group and Janus Henderson Investors) and continued support from existing investors suggests confidence in the company's execution and market position. Janus Henderson Investors, a global asset manager with significant institutional backing, signals institutional-grade validation of Calyxo's business model and clinical evidence base.
The funding level and investor composition indicate Calyxo has progressed substantially through its development and commercialization phases. Series F financings typically occur for companies with established market presence seeking to accelerate growth, expand indications, or scale manufacturing capacity. The specific use of proceeds was not detailed in the announcement.
The company specializes in kidney stone treatment solutions designed to enhance clinical outcomes for urologists. According to its positioning, Calyxo focuses on delivering what it characterizes as "paradigm-shifting solutions" that enable practitioners to achieve outcomes safely, effectively, and efficiently. The company's focus on a specific procedural market within urology—kidney stone intervention—represents a targeted approach to medical device innovation rather than a broad-based platform play.
This Series F round demonstrates sustained investor appetite for specialized medical device companies addressing defined clinical needs. The participation of both new lead investors (Ally Bridge Group and Janus Henderson Investors) and continued support from existing investors suggests confidence in the company's execution and market position. Janus Henderson Investors, a global asset manager with significant institutional backing, signals institutional-grade validation of Calyxo's business model and clinical evidence base.
The funding level and investor composition indicate Calyxo has progressed substantially through its development and commercialization phases. Series F financings typically occur for companies with established market presence seeking to accelerate growth, expand indications, or scale manufacturing capacity. The specific use of proceeds was not detailed in the announcement.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.